Alzheimer’s Drugs Market Size and Share - Global Forecast, 2022 - 2028

Alzheimer’s Drugs Market Size and Share - Global Forecast, 2022 - 2028

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.
Market Dynamics
Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2021, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2021, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to  prevent or delay symptoms of Alzheimer's disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2021, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.
Key features of the study:

This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global Alzheimer’s drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Alzheimer’s drugs market

Detailed Segmentation:

Global Alzheimer’s Drugs Market, By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

Global Alzheimer’s Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

Global Alzheimer’s Drugs Market, By Geography:

North America

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

U.S.
Canada

Latin America

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drugs:

Donepezil
Rivastigmine
Galantamine
Memantine

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Pfizer, Inc.*

Company Overview
Product Portfolio
Financial Performance
Recent Developments
Key Strategies

Janssen Pharmaceuticals
Novartis International AG
Eisai Co. Ltd
Lundbeck A/S
Teva Pharmaceuticals Industries Ltd
Daichi Sankyo Company Limited

“*” marked represents similar segmentation in other categories in the respective section.